Playing It Safe: How FDA Handles Its Risk-Related Buzz Words
Executive Summary
FDA is careful to exclude phrasing from labeling that might allow a product to claim a safety advantage if it is not definitively proven, but the agency is less strict about using the term "safer" outside the labeling context.
You may also be interested in...
FDA Discourages "Negative Safety Claims" In Labels Even At The Risk Of Inconsistency
FDA does not generally allow any claims in labeling that a safety issue does not exist with the product "because the evidence to support a conclusion of 'no effect' is very difficult to generate," the agency said. It's a policy that some academics say creates confusion, though.
FDA Discourages "Negative Safety Claims" In Labels Even At The Risk Of Inconsistency
FDA does not generally allow any claims in labeling that a safety issue does not exist with the product "because the evidence to support a conclusion of 'no effect' is very difficult to generate," the agency said. It's a policy that some academics say creates confusion, though.
Bayer's MRI Contrast Agent Gets Panel Endorsement, But Without Comparative Safety Claims
FDA's Peripheral and Central Nervous System Drugs Advisory Committee declines to deem gadobutrol "lower risk" for causing nephrogenic systemic fibrosis.